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Abstract
A primary goal of the recent investment in sequencing is to detect novel genetic associations
in health and disease improving the development of treatments and playing a critical role in
precision medicine. While this investment has resulted in an enormous total number of
sequenced genomes, individual studies of complex traits and diseases are often smaller
and underpowered to detect rare variant genetic associations. Existing genetic resources
such as the Exome Aggregation Consortium (>60,000 exomes) and the Genome Aggrega-
tion Database (~140,000 sequenced samples) have the potential to be used as controls in
these studies. Fully utilizing these and other existing sequencing resources may increase
power and could be especially useful in studies where resources to sequence additional
samples are limited. However, to date, these large, publicly available genetic resources
remain underutilized, or even misused, in large part due to the lack of statistical methods
that can appropriately use this summary level data. Here, we present a new method to incor-
porate external controls in case-control analysis called ProxECAT (Proxy External Controls
Association Test). ProxECAT estimates enrichment of rare variants within a gene region
using internally sequenced cases and external controls. We evaluated ProxECAT in simula-
tions and empirical analyses of obesity cases using both low-depth of coverage (7x) whole-
genome sequenced controls and ExAC as controls. We find that ProxECAT maintains the
expected type I error rate with increased power as the number of external controls
increases. With an accompanying R package, ProxECAT enables the use of publicly avail-
able allele frequencies as external controls in case-control analysis.
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Author summary
Recent investments have produced sequence data on millions of people with the number
of sequenced individuals continuing to grow. Although large sequencing studies exist,
most sequencing data is gathered and processed in much smaller units of hundreds to
thousands of samples. These silos of data result in underpowered studies for rare-variant
association of complex diseases. Existing genetic resources such as the Exome Aggregation
Consortium (>60,000 exomes) and the Genome Aggregation Database (~140,000
sequenced samples) have the potential to be used as controls in rare variant studies of
complex diseases and traits. However, to date, these large, publicly available genetic
resources remain underutilized, or even misused, in part due to the high potential for bias
caused by differences in sequencing technology and processing. Here we present a new
method, Proxy External Controls Association Test (ProxECAT), to integrate sequencing
data from different, previously incompatible sources. ProxECAT provides a robust
approach to using publicly available sequencing data enabling case-control analysis when
no or limited internal controls exist. Further, ProxECAT’s motivating insight, that readily
available but often discarded information can be used as a proxy to adjust for differences
in data generation, may motivate further method development in other big data technolo-
gies and platforms.
Introduction
Recent investments have produced sequence data on millions of people with the number of
sequenced individuals continuing to grow. Although large sequencing studies, such as the
Trans-Omics for Precision Medicine (TopMed) through the National Heart, Lung, and Blood
Institute, exist, most sequencing data is gathered and processed in much smaller units of hun-
dreds to thousands of samples. This is especially true in the study of diseases that are not very
common but still likely to have a complex or oligogenic genetic architecture. These silos of
data mean that most rare-variant association studies of uncommon, complex diseases are
underpowered. Zuk et al. suggest that sample sizes in the tens, and perhaps hundreds of thou-
sands are required for adequate power[1]. In addition to increasing the sample size of future
studies, fully leveraging existing sequencing resources could increase power considerably and
could be vital in scenarios where resources to sequence more samples are limited.
Existing genetic resources such as the Exome Aggregation Consortium (ExAC; >60,000
exomes)[2] and more recently, the Genome Aggregation Database (gnomAD; ~140,000
sequenced samples) have the potential to be used as controls in studies of complex diseases.
However, to date, these large, publicly available genetic resources remain underutilized, or
even misused[3], in large part due to the lack of statistical methods that can appropriately use
this summary level data in complex disease studies. In particular, there is a large potential for
bias caused by differences in sequencing technology, processing, and read depth[3].
Recently, Lee et al[4] developed iECAT, a method to incorporate publicly available allele
frequencies from controls into an existing, unbiased, but underpowered case-control analysis.
They found that iECAT controls for bias while increasing power to detect association to a
genetic region and can be applied to both single variant analysis and gene region analysis
using a SKAT-O framework[5]. iECAT cannot be applied to very rare variants such as single-
tons or doubletons and requires a set of controls that were sequenced and variant-called in
parallel to the cases (i.e. internal controls). Additionally, the type I error rate for iECAT
increases as the size of the internal control sample set decreases relative to the internal cases.
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Thus, there is still the need for methods that can incorporate very rare variants and external
controls without the explicit need for large internal control samples.
Here we present Proxy External Controls Association Test (ProxECAT), a method to esti-
mate enrichment of rare variants within a gene region using internal cases and external con-
trols. Our method addresses existing gaps such as using singleton and doubleton variants and
requiring only external controls.
Rare-variant tests in a gene are often limited to variants predicted to have a functional effect
on the protein, hence discarding non-functional variants. This can result in greater power[6,
7]. The development of ProxECAT was motivated by the observation that these discarded vari-
ants can be used as a proxy for how well variants within a genetic region are sequenced and
called within a sample. ProxECAT is both simple and fast, requiring only allele frequency
information, and is thus well suited to use publicly available resources such as ExAC and
gnomAD.
We evaluate ProxECAT in simulations, and empirical analysis of high depth of coverage
(80x) whole-exome sequenced childhood obesity cases (N = 927) using both low-depth of cov-
erage (7x) whole-genome sequenced controls (N = 3,621), and ExAC (N = 33,370). Our
method controls the type I error rate in simulations and yields the expected distribution of test
statistics in real data settings. Given an accompanying R package, ProxECAT provides a robust
and previously unavailable method to use publicly available allele frequencies as external con-
trols in case-control analysis. This increases the utility of existing sequenced datasets to gener-
ate hypotheses and further research into the genetic basis of disease.
Results
Proxy external controls association test
For a gene region-based test, we consider the following. Let Y denote the disease status, with
Y = 1 and Y = 0 for internal case and external control status, respectively. We split the variants
into those that are predicted to have a functional genetic impact and those that are not pre-
dicted to have a functional impact. We use the latter as the proxy variants. Let, xf1 and x
p
1 denote
the counts of the functional and proxy rare variant alleles respectively for internal cases and xf0
and xp0 denote the counts of functional and proxy rare variant alleles respectively for external
controls (Table 1).
We model the observed variant minor allele counts in Table 1 as a random sample from
four independent Poisson distributions, i.e., Xf1 � Poisðl
f
1
Þ;Xf0 � Poisðl
f
0
Þ;Xp1 � Poisðl
p
1
Þ, and
Xp0 � Poisðl
p
0
Þ. The derivation of the ProxECAT test statistic follows from the null hypothesis
in Eq (1):
H0 :
l
f
1
l
p
1
¼
l
f
0
l
p
0
: ð1Þ
Table 1. Data notation for internal case and external control samples for ProxECAT.
Predicted Functional Impact Total
Functional Not Functional (Proxy)
Cases (Internal) Y = 1 xf1 x
p
1 x1
Controls (External) Y = 0 xf0 x
p
0 x0
Total xf xp
https://doi.org/10.1371/journal.pgen.1007591.t001
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Using the method of Lagrange Multipliers and the constraint as defined by the null hypoth-
esis, we find the maximum likelihood estimates (MLEs) of our parameters: l
f
1
; l
p
1
; l
f
0
; l
p
0
.
Details are in S1 Appendix.
Our MLEs under the null hypothesis are:
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We use the parameter estimates in the likelihood for the constrained null hypothesis. The
MLEs for the unconstrained alternative hypothesis parameters are the variant allele counts for
each group (i.e. ~l
f
1 ¼ x
f
1;
~l
f
0 ¼ x
f
0;
~l
p
1 ¼ x
p
1;
~l
p
0 ¼ x
p
0). We then complete a likelihood ratio test
(LRT) as the ratio of the constrained (null hypothesis) and unconstrained (alternative hypothe-
sis) likelihoods, which, by Wilk’s theorem[8] can be transformed to have a chi-squared distri-
bution with 1-df.
Extension to incorporate different depths of coverage
It has been shown that functional variants have a lower minor allele frequency (MAF) distribution
compared to synonymous variants[9]. Further, high-depth of coverage sequencing will detect a
higher amount of variation at lower MAFs compared to low-depth of coverage sequencing[9, 10].
This results in high-depth of coverage sequencing detecting more functional variation relative to
synonymous variation compared to low-depth of coverage sequencing. To allow for scenarios
where sequencing coverage varies considerably between cases and controls, we weight the
observed functional variant minor allele counts. Specifically, we divide the number of minor
alleles for functional variants by the median ratio of the number of minor alleles for functional to
synonymous variants within cases (M1) and within controls (M0) separately:
xf1;weighted ¼
xf1
M1
xf0;weighted ¼
xf0
M0
:
The weighted functional variant minor allele counts, xf1;weighted and x
f
0;weighted, are used in place
of the observed functional variant minor allele counts, xf1 and x
f
0, respectively to estimate the
parameters in (2). This new test statistic is called ProxECAT-weighted.
Extension to negative binomial
By assuming a Negative Binomial distribution for the number of minor alleles in a region
instead of a Poisson distribution, we extend ProxECAT to incorporate possible over-
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dispersion. We model the Negative Binomial distribution with the mean, λ, and over-disper-
sion, η, parameters where the distribution approaches Poisson as η becomes large (S1 Fig).
Type I error and power simulation results
We simulated a variety of confounding scenarios. Case-control confounding represents sys-
tematic, genome-wide differences in the number of rare minor alleles observed in cases and
controls due to differences in sequencing technologies and pipelines. Gene confounding refers
to a gene having a higher or lower number of rare minor alleles than expected based on gene
length. Gene confounding can occur in both cases and controls for a variety of reasons includ-
ing differences in mutation rates, ability to detect variants, and annotation quality. Confound-
ing can also occur when a particular gene region has a different number of rare minor alleles
in cases and in controls due to sequencing differences between cases and controls. This con-
founding is distinct from case-control confounding in that it is isolated to a particular gene
region rather than genome-wide. Here, we refer to this confounding as gene confounding only
in cases. The simulation scenarios and parameters are presented in Table 2 and Supplemental
Table 1.
The case-control LRT (see Software and Statistical Analysis under Subjects and Methods)
was robust to gene confounding scenarios maintaining the appropriate type I error rate but
had an increased type I error rate in the presence of case-control confounding. The case-only
LRT maintained appropriate type I error rate in the presence of case-control confounding but
was inflated in the presence of gene-confounding. The inflation in the type I error for the case-
control LRT and the case-only LRT increased further when both gene and case-control con-
founding were present. This was especially true for the case-control LRT (Fig 1).
Despite usually being within the 95% confidence interval for type I error, ProxECAT
appeared to have a slight, but consistent inflation (Supplemental Table 2). This minor, but con-
sistent inflation in the type I error rate can be addressed by using a more conservative signifi-
cance threshold. We found that multiplying the significance level by 0.9 works well such that a
0.045 significance threshold maintains a 0.05 type I error rate, a 0.009 significance threshold
maintains a 0.01 type I error rate, etc. Both the case-control LRT used here and ProxECAT
assume a Poisson distribution and had inflated Type I Error rate in the presence of overdisper-
sion (S3 Table). ProxECAT-over, which assumes a Negative Binomial distribution instead of a
Poisson distribution, corrects for overdispersion in simulations when the overdispersion
parameter is known and overdispersion is not too extreme (i.e. over-dispersion, η� 5) (S3
Table).
Case-control LRT had higher power than ProxECAT under scenarios of no case-control
confounding and given the same sample size (S4 Table). However, the power of ProxECAT
increased as the sample size of the external control set increased eventually reaching higher
Table 2. Simulation parameters.
Baseline variant minor allele rate 0.001 per subject per 1Kb
Association variant minor allele rate 0.001 � (1.2, 1.4, 1.6, 1.8, 2, 3)
Gene length 20, 40 Kb
Case set sample size 500, 1000
Control set sample size 500, 1000, 10000, 40000, 100000
Gene confounding In cases and controls: 0.001 � (1, 1.2, 1.5, 2)
Only in cases: 0.001 � (1, 1.2, 1.5, 2)
Case control confounding In cases: 0.001 � (1, 1.1, 1.3, 1.5)
https://doi.org/10.1371/journal.pgen.1007591.t002
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power than the case-control LRT for the same number of internal sequences (Fig 1). This
increase in power for ProxECAT is due, in part, to being able to sequence more cases with
ProxECAT (N = 1000) than with a case-control LRT where sequencing resources need to be
split between cases and controls (here Ncases = 500 and Ncontrols = 500). ProxECAT’s power
increased while the type I error stayed the same under confounding scenarios where the num-
ber of functional variants in the cases increases (S4 Table).
Assessing fit of the Poisson distribution
To assess the fit of the Poisson distribution and specifically look for over dispersion, we simu-
lated rare minor alleles assuming a Binomial distribution for each variant and compared these
Fig 1. Type I error and power estimates for case-only LRT, case-control LRT, and ProxECAT. Estimates provided
over various confounding simulation scenarios. General simulation parameters: gene-length = 20Kb, baseline
mutation rate = 0.001 per person per 1Kb. Left Plot: type I error rate for Ncases = Ncontrols = 1000 and combinations of
case-control confounding (mid level) and gene confounding (low level); dashed line represents expected type I error
rate of 0.05 and dotted lines represent 95% confidence interval around the expected type I error rate. (A) Null
simulation with no case-control or gene confounding bias; (B) gene-confounding; (C) gene-confounding only in cases;
(D) case-control confounding; (E) case-control confounding and gene confounding; (F) case-control confounding and
gene confounding only in cases. Right Plot: power for an effect size of 2 for case-control LRT (Ncases = 500;
Ncontrols = 500) and ProxECAT (Ncases = 1000) and various external controls sample size. Dashed line is the case-
control LRT power and dotted lines represent 95% confidence interval around the estimated power for case-control
LRT.
https://doi.org/10.1371/journal.pgen.1007591.g001
Fig 2. Quantile-Quantile plots for SCOOP cases vs. UK10K Cohort controls. Internal MAF< 0.01 in both cases
and controls and number of variant minor alleles per gene� 5. N genes = 11,051. 95% confidence interval of expected
results in gray. ProxECAT (blue, lambda = 3.151), ProxECAT-weighted (orange, lambda = 1.026), case-control (black,
lambda = 1.971). A) all tests, B) ProxECAT-weighted only.
https://doi.org/10.1371/journal.pgen.1007591.g002
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results to the theoretical Poisson distribution for the number of rare minor alleles in a genetic
region. No over dispersion was apparent as the sampling mean and variance of the simulated
scenarios were similar across different sample sizes, MAFs, and number of minor alleles per
gene (S2 and S3 Figs). When the expected number of minor alleles per gene was greater than
20, the Poisson approximation for the number of minor alleles started to look more continu-
ous. In other words, as the expected number of variants per gene decreased, the Poisson
approximation became more discrete and multimodal (S2 and S3 Figs). The theoretical distri-
bution for the number of minor alleles per gene created from simulating genotypes for individ-
ual, independent variants from a Binomial distribution was more robust to discretization
maintaining a mostly continuous distribution until the expected number of minor alleles per
gene was equal to or less than four.
SCOOP data analysis
We evaluated ProxECAT using 926 cases from the Severe Childhood Onset Obesity Project
(SCOOP) sample as cases and either 3,621 UK10K Cohort or 33,370 ExAC non-Finnish Euro-
peans as controls. High-depth of coverage WES SCOOP cases vs. low-depth of coverage WGS
UK10K Cohort controls had an inflated distribution of test statistics for the case-control LRT
both at the center (lambda = 1.971) and in the tail of the distribution. While we did not observe
inflation in the tail of the distribution for ProxECAT (Fig 2), there was a large inflation in the
overall distribution of test statistics (lambda = 3.151). We observed a much higher ratio of the
number of minor alleles in functional to synonymous variants per gene for the high-depth of
coverage cases, median = 3.00, versus the low-depth of coverage controls, median = 1.89
(Table 3). ProxECAT-weighted, which adjusts for this systematic difference in sequencing cov-
erage, resulted in a distribution of observed test statistics that more closely matches the
expected distribution (lambda = 1.026, Fig 2).
A large strength of this method is the ability to use allele frequency data directly, rather
than individual level allele calls. To assess the ability of this method to use publicly available
allele frequency data, we used ExAC allele frequencies as controls for the SCOOP cases. The
standard case-control LRT was inflated at both the median, lambda = 1.713, and tail (Fig 3)
while our method maintained the expected distribution of test statistics. Because the depth of
sequencing coverage is comparable and high for both SCOOP cases and ExAC controls,
ProxECAT-weighted produced similar results to the standard, un-weighted test.
For both analyses, filtering to very rare variants was essential to avoid inflation in the distri-
bution of observed test-statistics. This can be accomplished using moderate internal frequency
filters and an external dataset such as 1000Genomes (MAF < 1%) as in the SCOOP vs UK
Cohort analysis or using more stringent internal frequency filters (MAF < 0.1%) and no exter-
nal dataset as in the SCOOP vs ExAC analysis.
Four genes, passing a 0.01 level of significance in both the SCOOP vs UK10K Cohort analy-
sis and in the SCOOP vs ExAC analysis, are shown in Table 4. These results are putative novel
obesity candidates meriting further replication. MIB2 may be of particular interest as it is
Table 3. Genome-wide descriptive statistics for the ratio of the number of functional and synonymous variant minor alleles per gene in cases and controls.
min Q1 Median Q3 Max
SCOOP vs UK10K Cohort SCOOP cases 0.01 2.00 3.00 6.00 124
UK10K Cohort controls 0.02 1.02 1.89 3.33 120
SCOOP vs ExAC SCOOP cases 0.07 1.00 1.40 3.00 29
ExAC 0.02 1.00 1.65 2.55 109
https://doi.org/10.1371/journal.pgen.1007591.t003
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associated with decreased body weight in mice in the International Mouse Phenotyping Con-
sortium (p-value = 7.49�10−10, http://www.mousephenotype.org/data/genes/MGI:2679684).
Additional genes with the smallest p-values are found in S5–S7 Tables.
Sensitivity of proxy selection
Within the SCOOP vs. ExAC analysis, we completed a sensitivity analysis using three increas-
ingly broad proxy selection strategies of Sequence Ontology terms: (1) synonymous (SYN); (2)
predicted low impact rating from Ensembl [11] (LOW); and (3) not in our functional category
(NOT FUNC). These strategies are nested with LOW Sequence Ontology terms included in
NOT FUNC, and SYN Sequence Ontology terms included in both LOW and NOT FUNC. We
assessed consistency across the number of alternate alleles and in the distribution of test statis-
tics across the three proxy selection strategies.
As expected given the nested nature of the proxy selection strategies, SYN had a smaller
number of alternate alleles than either LOW or NOT FUNC and LOW had a smaller number
of alternate alleles than NOT FUNC. SYN and LOW proxy selection strategies produced simi-
lar numbers of alternate alleles per gene while the correlation was lower for NOT FUNC with
either SYN or LOW (S4 Fig). We found similar consistency in the distributions of test statistics
between the proxy selection strategies (S5 Fig).
Fig 3. Quantile-Quantile plots for SCOOP cases vs. ExAC controls. Internal MAF< 0.001 in both cases and
controls and number of variant minor alleles per gene� 5. N genes = 15,863. 95% confidence interval of expected
results in gray. ProxECAT (blue, lambda = 1.163), ProxECAT-weighted (orange, lambda = 1.069), case-control (black,
lambda = 1.713) A) all tests, B) ProxECAT and ProxECAT-weighted only.
https://doi.org/10.1371/journal.pgen.1007591.g003
Table 4. Gene-based results for genes with p–value< 0.01 in SCOOP vs. Cohort and SCOOP vs ExAC.
SCOOP vs Cohort SCOOP vs ExAC
SCOOP Cohort p-values SCOOP ExAC p-values
ProxECAT ProxECAT case ProxECAT ProxECAT case
Gene xf1=x
p
1 x
f
0=x
p
0 weighted control x
f
1=x
p
1 x
f
0=x
p
0 weighted control
CD22 15/0 13/18 1.1E-05 2.1E-03 1.1E-04 16/1 380/247 1.5E-03 1.4E-03 1.3E-01
MIB2 0/8 62/16 1.9E-06 1.2E-04 1.1E-07 0/4 600/361 5.2E-03 1.8E-02 9.8E-09
NDEL1 13/0 18/25 1.7E-05 2.0E-03 6.6E-03 11/1 357/268 8.1E-03 5.7E-03 7.4E-01
PRDM13 9/0 13/33 1.1E-05 8.0E-03 2.9E-02 7/0 173/116 7.8E-03 6.8E-03 3.6E-01
https://doi.org/10.1371/journal.pgen.1007591.t004
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Discussion
We propose a new method, ProxECAT, to test for enrichment of an accumulation of very rare
variant alleles in a gene-region using publicly available external allele frequencies. ProxECAT only
requires allele frequencies and uses exclusively external controls enabling the use of large, publicly
available datasets such as ExAC and gnomAD. Analyses in simulations and using UK10K Cohort
and ExAC as control sets for childhood obesity cases show that ProxECAT keeps the type I error
rate and expected distribution of test statistics under control despite differences in sequencing
technology and processing. Because ProxECAT uses external controls, additional resources can
be devoted to sequencing cases. This results in greater power for ProxECAT compared to the
case-control LRT test for the same number of internally sequenced individuals.
There are several limitations to the method proposed here. First, ProxECAT has a minor,
but consistent inflation in the type I error rate. This limitation is easily addressed by using a
more conservative significance threshold. Second, ProxECAT cannot currently include covari-
ates such as sex, and ancestry. Thus, internal cases and external controls should be closely
matched by ancestry and, as with any association study, findings will need independent repli-
cation preferably using a study where cases and controls are sequenced and processed in paral-
lel. Third, the current approach does not enable internal controls to be analyzed along with
external controls. While two analyses can be done in parallel and compared, it would be ideal
to incorporate internal and external controls into the same statistical test. We are actively
working on extensions to address these limitations.
It is important to highlight that research utilizing solely external controls is more suscepti-
ble to confounding due to known or unknown factors. Thus, any genes identified using ProxE-
CAT or any method that uses only external controls should be carefully followed up in further
validation, replication, and functional studies.
ProxECAT provides a robust approach to using allele frequencies from existing, publicly
available sequencing data enabling case-control analysis when no or limited internal controls
exist. ProxECAT uses the insight that readily available genomic information often discarded
from analyses (here synonymous variation) can adjust for sizeable confounding due to differ-
ences in data generation. In the era of big data, we hope that both this insight and the ProxE-
CAT method will enable additional genetic discoveries and will also motivate future
methodological advancements in analyzing data across technologies and platforms.
Materials and methods
Software and statistical analysis
All tests were implemented using functions from our accompanying R package ProxECAT (https://
github.com/hendriau/ProxECAT). Our primary test, which can model both ProxECAT and ProxE-
CAT-weighted, was implemented with the proxecat function and our secondary test modeling
over-dispersion was implemented using the proxecat.over function. We also implemented a case-
control LRT to test for enrichment of rare, functional variant alleles in cases vs. controls and a case-
only LRT similar to that performed by Zhi and Chen in 2012 [12]. The case-only LRT tests for
enrichment of rare alleles for functional variants in each gene of interest compared to the genome-
wide average number of minor alleles per gene in cases only adjusting for the length of each gene.
Unless otherwise specified, we assumed the data follow a Poisson distribution for all LRTs.
Type I error and power simulations
Within each case-control confounding simulation, we simulated 20,000 independent genes
under four gene-disease association and gene confounding states. The four distinct gene states
ProxECAT: A new case-control gene region association test using allele frequencies from public controls
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are: (1) association with case status and no gene confounding, (2) association with case status
and gene confounding, (3) no association with case status and gene confounding, (4) no asso-
ciation with case status and no gene confounding. The number of rare minor alleles per gene
was simulated under a Poisson distribution or an over-dispersed Poisson modeled using a
Negative Binomial parameterization using the R functions rpois and rnbinom, respectively.
The mu and size parameters in rnbinom represent the mean and over-dispersion, respectively.
Assessing fit of the Poisson distribution
To assess the fit of the Poisson distribution, we simulated the number of each genotype group
for each variant assuming Hardy-Weinberg Equilibrium and a Binomial distribution where p
was the MAF. We varied the MAF (0.0001, 0.0005, 0.001, 0.005), the sample size (1000;
10,000), and the maximum number of variable variants within the gene region (5, 10, 20). We
then assessed how closely the simulated distributions of the number of minor alleles observed
per gene region matched a theoretical Poisson distribution where λ was the mean from each
simulation scenario.
UK10K SCOOP
Whole-exome sequenced (WES) cases are from the Severe Childhood Onset Obesity Project
(SCOOP) cohort[6, 13], which is a self-reported UK European subset of the Genetics of Obe-
sity Study (GOOS). GOOS includes individuals with severe early-onset obesity body mass
index (BMI) standard deviation score (SDS)> 3 and age at onset of obesity < 10 years. Leptin
deficient individuals (identified by biochemical measurement) and those with mutations in
the MC4R gene were excluded.
We used VerifyBamID (v1.0)[14] and a threshold of�3% to identify contaminated sam-
ples. We computed principal components with the 1000Genomes Phase I integrated call set[9]
using EIGENSTRAT v4.2[15] to identify non-Europeans, and pairwise identity by descent esti-
mates from PLINK v1.07[16] with a threshold of�0.125 to identify related individuals. Con-
taminated, non-European, and related samples were removed resulting in 927 SCOOP cases
for analysis. Details about sequencing and variant calling for the SCOOP cases, as part of the
UK10K exomes can be found elsewhere[17]. All participants gave written informed consent
and all methods were performed in accordance with the relevant laboratory/clinical guidelines
and regulations.
UK10K cohort
The whole-genome sequenced (WGS) controls consist of the UK10K Cohort sample, com-
prised of two population cohorts: the Avon Longitudinal Study of Parents and Children
(ALSPAC) and the TwinsUK study from the Department of Twin Research and Genetic Epi-
demiology at King’s College London (TwinsUK). We used allele frequency data for 3,621 indi-
viduals that passed sample QC as described elsewhere[17].
Exome aggregate consortium
We used allele frequency values for the N = 33,370 non-Finnish European (NFE) group from
the ExAC variant site dataset version 1.0 (http://exac.broadinstitute.org/downloads)[2].
Variant and gene filtering
To focus on rare or very rare variants, we limited to variants below a pre-specified MAF
threshold in both cases and controls. We used MAF� 1% in the SCOOP cases vs. UK10K
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cohort controls analysis and MAF� 0.1% in the SCOOP vs. ExAC analysis. For the SCOOP
cases vs. UK10K controls analysis, we also applied external filtering excluding variants with a
MAF > 1% in at least one of the 1000Genomes five primary ancestry groups. Exclusion by
1000Genomes MAF was not possible when using ExAC as 1000Genomes sample are included
in the ExAC genotype frequencies. We explored the distribution of test statistics over several
thresholds for the minimum number of functional (xf) and proxy (xp) variants within each
gene (5, 10, and 20).
Analysis regions were limited to the intersection of respective target regions for SCOOP vs.
UK10K Cohort and for SCOOP vs. ExAC. All variant annotation was applied using the
GRCh37 human reference. The Ensembl Variant Effect Predictor (VEP, http://www.ensembl.
org/info/docs/tools/vep/index.html [11] v79 and v90.1) from Ensembl was used to add variant
consequence annotations for SCOOP vs. UK10K Cohort and SCOOP vs. ExAC respectively.
We defined functional variation using the following Sequence Ontology terms[18] variant
consequences: splice_donor_variant, splice_acceptor_variant, stop_gained, frameshift_var-
iant, stop_lost, initiator_codon_variant, inframe_insertion, inframe_deletion, missense_var-
iant, and protein_altering_variant. Variants were considered synonymous if they had the
“synonymous_variant” flag. We defined the LOW proxy group as having a predicted low
impact rating from Ensembl, SO terms: splice_region_variant, incomplete_terminal_codon_-
variant, stop_retained_variant, synonymous_variant.
Assessing results from real data analysis
We used quantile-quantile plots (QQ-plots) to assess the resulting distribution of test statistics
from the real data applications. Specifically, we looked at the middle of the distribution of test
statistics as assessed by the lambda value (i.e. the median of the observed test statistic divided
by the median of the expected test statistic) and the tail of the distribution of test statistics,
which we assessed visually.
R Package. ProxECAT R package and functions are available on github: https://github.
com/hendriau/ProxECAT.
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